Biosimilars, Beginning a Conversation
Phoenix, AZ US
November 7, 2015
Learning Objectives
- Discuss the history and importance of biosimilars in oncology
- Describe the current landscape of biotherapeutics in oncology
- Discuss the current pathway for US Food and Drug Administration (FDA) approval of biosimilars
- Define the potential clinical implications associated with biosimilars and biotherapeutics for advanced practitioners working in oncology
JW Marriott Desert Ridge
5350 East Marriott Drive
Phoenix, AZ
85054
United States
Chris Campen, PharmD, BCPS, BCOP
Ali McBride, PharmD, BCPS, BCOP
Kelley Mayden, MSN, FHP, AOCNP
Available Credit
- 1.00 AANP
- 0.83 Pharmacology
- 1.00 ACPE
- 1.00 AMA PRA Category 1 Credit(s)™
- 1.00 Attendance
- 1.00 ANCC